Salazar, Antony Brayan Campos; Genvigir, Fabiana Dalla Vecchia; Felipe, Claudia R; Silva Junior, Helio Tedesco; Pestana, José O. Medina; Monteiro, Gabriela V; Basso, Rodrigo G; Cerda, Alvaro; Hirata, Mario Hiroyuki 
; Hirata, Rosario Dominguez Crespo
Source: Frontiers in Pharmacology. Unidade: FCF
Subjects: POLIMORFISMO, TRANSPLANTE DE RIM
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SALAZAR, Antony Brayan Campos et al. Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients. Frontiers in Pharmacology, v. 9, p. 1-11 art. 1296, 2018Tradução . . Disponível em: https://doi.org/10.3389/fphar.2018.01296. Acesso em: 14 nov. 2024.APA
Salazar, A. B. C., Genvigir, F. D. V., Felipe, C. R., Silva Junior, H. T., Pestana, J. O. M., Monteiro, G. V., et al. (2018). Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients. Frontiers in Pharmacology, 9, 1-11 art. 1296. doi:10.3389/fphar.2018.01296NLM
Salazar ABC, Genvigir FDV, Felipe CR, Silva Junior HT, Pestana JOM, Monteiro GV, Basso RG, Cerda A, Hirata MH, Hirata RDC. Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients [Internet]. Frontiers in Pharmacology. 2018 ; 9 1-11 art. 1296.[citado 2024 nov. 14 ] Available from: https://doi.org/10.3389/fphar.2018.01296Vancouver
Salazar ABC, Genvigir FDV, Felipe CR, Silva Junior HT, Pestana JOM, Monteiro GV, Basso RG, Cerda A, Hirata MH, Hirata RDC. Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients [Internet]. Frontiers in Pharmacology. 2018 ; 9 1-11 art. 1296.[citado 2024 nov. 14 ] Available from: https://doi.org/10.3389/fphar.2018.01296
